Kodiak Sciences Inc stock (US50012K1051): earnings loss widens as biotech pushes retina pipeline
Kodiak Sciences Inc. reported widening losses for Q4 2025, with an EPS loss of -0.94 USD, slightly missing analyst expectations. As a clinical-stage biopharmaceutical company, Kodiak is heavily investing in its ophthalmology pipeline, focusing on therapies for retinal diseases like age-related macular degeneration. The company's valuation remains tied to clinical trial progress, regulatory approvals, and access to capital rather than current revenues, highlighting the high-risk, high-reward nature for investors in the biotech sector.
Kodiak Sciences Inc stock (US50012K1051): what’s behind the latest volatility after eye disease setback?
Kodiak Sciences Inc. (KOD) shares are experiencing volatility due to past clinical setbacks in its eye disease therapies and ongoing pipeline restructuring. The clinical-stage biopharmaceutical company focuses on developing antibody-based treatments for retinal diseases and relies on capital markets to fund its research, as it currently has no approved products generating revenue. Investors track KOD for its potential in significant retinal disease markets, despite the high risks associated with clinical drug development.
Boxer Capital Management Boosts Kodiak Sciences Holdings in Q1 2026 - News and Statistics
Boxer Capital Management significantly increased its holdings in Kodiak Sciences during Q1 2026, purchasing an additional 225,000 shares valued at an estimated $5.81 million. This transaction brought their total stake to 1,361,000 shares, representing 6.81% of their reportable assets under management and making Kodiak Sciences their second-largest holding. Kodiak Sciences, a clinical-stage biotechnology company focused on retinal diseases, has seen its stock outperform the S&P 500 over the past year.
Kodiak Sciences Inc stock (US50012K1051): Investors eye eye-disease pipeline after latest company up
Kodiak Sciences Inc (KOD) is garnering investor attention following its recent pipeline and corporate update, which highlighted progress in its retinal disease programs. Despite previous trial setbacks, the biotech firm is now outlining next development steps for its key drug candidates. As a development-stage company, Kodiak's valuation is heavily influenced by expectations for future clinical and regulatory milestones, rather than current product revenue.
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30
This article reports that the price target for Kodiak Sciences (KOD) has been increased by 16.91%, raising it to $66.30. The content provided is minimal, only stating the new price target.
Sirenia Capital (KOD) and Alex Silverstein report 3,495,000 shares (5.7%)
Sirenia Capital Management and Alex Silverstein have reported beneficial ownership of 3,495,000 shares of Kodiak Sciences Inc. common stock, representing a 5.7% stake. This stake is held by SILV Fund, Ltd., which is managed by Sirenia, and both parties filed jointly. The percentage is calculated based on 61,847,870 shares outstanding as of March 19, 2026, with shared voting and dispositive power over the shares.
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30
This article reports that the price target for Kodiak Sciences (KOD) has been increased by 16.91%, raising it to $66.30. It focuses solely on this specific financial update.
Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus
Kodiak Sciences Inc. reported a Q4 2025 EPS of -$0.94, missing analyst estimates by $0.01, as per its May 7, 2026 earnings release. The biotech firm, specializing in retinal therapies, continues to advance its lead candidate, KSI-301, through clinical trials, focusing on long-duration treatments for conditions like AMD and DME. Investors are anticipating the next earnings report due around May 13, 2026, for updates on its pipeline and financial status.
Chardan Capital upgrades Kodiak Sciences (KOD)
This article states that Chardan Capital has upgraded Kodiak Sciences (KOD). No further details about the upgrade or the company are provided in the given content.
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58
H.C. Wainwright has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained a target price of $58. This indicates the firm's continued positive outlook on the company's stock performance.
Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value
Kodiak Sciences reported positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, showcasing superiority over sham treatment and strengthening its retinal pipeline. This data supports a potential multi-indication BLA submission, validating Kodiak's ABC platform. While the stock has seen significant returns, investors are now focused on execution and regulatory progress, particularly regarding Zenkuda's commercialization prospects.
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda
Kodiak Sciences (KOD) is under scrutiny after positive Phase 3 GLOW2 results for Zenkuda, amidst a 90-day share price return of nearly 90%. While the stock trades below the average analyst target, its price-to-book ratio is significantly higher than peers and the biotech industry, with continued losses and no projected revenue for next year. The article highlights a discrepancy between valuation methods, with the P/B indicating overvaluation while a DCF model suggests it's undervalued.
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences reported a wider-than-expected loss of 94 cents per share in Q1 2026, though its cash position is expected to support operations into 2027. The company is focusing on its pipeline, with positive Phase III data for Zenkuda in diabetic retinopathy leading to accelerated regulatory submission. Key upcoming milestones include top-line data from the DAYBREAK study in September 2026 and pivotal Phase III results for KSI-101 in late 2026 and Q2 2027.
Kodiak Sciences 1Q Loss $58.2M >KOD
Kodiak Sciences reported a first-quarter loss of $58.2 million. The company, identified by the stock symbol KOD, announced these financial results recently. This information provides key financial performance data for investors and stakeholders.
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
This press release from Kodiak Sciences announces recent business highlights and the company's first-quarter 2026 financial results. It provides an overview of the company's performance and significant developments during that period.
Kodiak Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
Kodiak Sciences (KOD) reported its Quarterly Report for the Quarter Ending March 31, 2026, detailing its precommercial biotechnology focus on retinal therapeutics. The report highlights progress in its late-stage clinical programs, including Zenkuda (tarcocimab), KSI-501, and KSI-101, with Zenkuda BLA submission planned for 2026. The company also discussed financial results, showing a net loss of $58.158 million for the quarter, and liquidity challenges, stating that current cash and cash equivalents will support operations into 2027, but additional funding will be required.
Kodiak Sciences (NASDAQ: KOD) posts Q1 loss, highlights strong Phase 3 data
Kodiak Sciences reported a Q1 2026 net loss of $58.2 million but highlighted strong Phase 3 data for Zenkuda in diabetic retinopathy, showing significant improvement and reduced complications. The company anticipates key topline data readouts for Zenkuda and KSI-501 in wet AMD (Q3 2026) and KSI-101 in macular edema secondary to inflammation (Q4 2026 and Q2 2027), with sufficient cash to fund operations into 2027.
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue?
This article discusses Kodiak Sciences (KOD) stock performance, noting a 2% increase since its last earnings report. It poses the question of whether this upward trend can be sustained, indicating a focus on the company's financial outlook and investor sentiment post-earnings.
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue?
Kodiak Sciences (KOD) has seen a 2% increase in its stock price since its last earnings report. This article discusses factors that could influence whether the company can maintain this positive momentum, particularly ahead of its upcoming earnings call.
Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC
RIA Advisory Group LLC significantly reduced its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 31.9% in the fourth quarter, selling over 53,000 shares but still retaining a substantial holding valued at approximately $3.17 million. Despite this reduction, institutional ownership in Kodiak Sciences remains high at 89.06%, and analysts have a "Moderate Buy" consensus rating with UBS raising its price target to $80. The company's stock currently trades at $43.96 with a market cap of $2.73 billion.
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Kodiak Sciences will present new clinical data for its eye drug KSI-101 at upcoming scientific conferences, including positive results from an Asian cohort of patients with macular edema secondary to inflammation (MESI). The data showed significant visual and anatomical improvements, mirroring previous U.S. study results, and supports the global expansion of its Phase 3 PEAK and PINNACLE trials. The company will also highlight advances in its bispecific therapies for geographic atrophy and ocular inflammatory diseases, and its ABCD platform for multi-modal drug delivery.
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue?
This article analyzes Kodiak Sciences' (KOD) stock performance since its last earnings report, noting a 2% increase. It speculates on the factors that could influence its future trajectory, including upcoming earnings, analyst revisions, and overall industry trends.
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Kodiak Sciences (KOD) has seen its shares rise 2% since its last earnings report, underperforming the S&P 500. The company reported a wider-than-expected loss in Q4 2025, with increased R&D expenses and no approved products generating revenue. Despite a significant increase in cash, estimates for the stock have been trending downward, resulting in a Zacks Rank #3 (Hold).
Diabetic Retinopathy Pipeline Set for Transformational Breakthroughs by 2026 with 55+ Therapies expanding Clinical Innovation from Kodiak Sciences, Regenxbio, Adverum Biotechnologies | DelveInsight
The Diabetic Retinopathy (DR) pipeline is poised for significant advancements by 2026, with over 55 therapies from companies like Kodiak Sciences, Regenxbio, and Adverum Biotechnologies. These innovations focus on novel mechanisms, sustained drug delivery, and gene therapies to address the progressive vision-threatening condition. DelveInsight's report highlights a diverse therapeutic landscape with increasing clinical trial activity and strategic collaborations aimed at improving patient outcomes.
Diabetic Retinopathy Pipeline Set for Transformational
The diabetic retinopathy treatment landscape is experiencing significant innovation with over 55 therapies from more than 50 companies, including Kodiak Sciences, Regenxbio, and Adverum Biotechnologies, advancing through clinical trials by 2026. DelveInsight's "Diabetic Retinopathy Pipeline Insight, 2026" report highlights a shift towards novel mechanisms, long-acting delivery systems, and gene therapies to address the progressive vision-threatening condition. Key emerging drugs like Tarcocimab tedromer (Kodiak Sciences), VX-01 (Vantage Biosciences), and THN391 (Therini Bio) are detailed, alongside recent clinical trial announcements.
BlackRock (KOD) holds 3.27M shares, a 5.3% stake in Kodiak Sciences (KOD)
BlackRock, Inc. has reported a 5.3% passive stake in Kodiak Sciences Inc. (KOD), holding 3,273,386 shares of Common Stock as of March 31, 2026. The Schedule 13G filing indicates BlackRock has sole voting power over 3,221,479 shares and sole dispositive power over all 3,273,386 shares. This makes BlackRock a substantial institutional holder in Kodiak Sciences, with the filing signed on April 27, 2026.
Kodiak Sciences Reports Positive Trial Results for Diabetic Retinopathy
Kodiak Sciences Inc. announced positive Phase 3 trial results for its experimental drug Zenkuda in treating diabetic retinopathy. The drug showed significant improvement rates compared to a control group and reduced the risk of vision-threatening complications. Following these results, H.C. Wainwright increased its price target for Kodiak Sciences and raised the probability of success for Zenkuda in diabetic retinopathy and wet age-related macular degeneration.
Kodiak Q4 loss wider than expected, pipeline development in focus
This article reports that Kodiak's Q4 loss was worse than anticipated, which means the company lost more money than financial analysts had predicted for that quarter. The article also highlights that the company's focus is currently on the development of its product pipeline, suggesting future growth and innovation are key priorities despite the recent financial setback.
[ARS] Kodiak Sciences Inc. SEC Filing
This article reports on an ARS SEC filing by Kodiak Sciences Inc. (KOD) on April 22, 2026. The filing indicates a "Low" impact and "Neutral" sentiment. The article also provides an overview of Kodiak Sciences Inc., including its stock rankings, recent news, and other SEC filings.
Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?
Kodiak Sciences Inc. (NASDAQ: KOD) has shown promising results from a Phase 3 trial of its drug Zenkuda (tarcocimab tedromer) for diabetic retinopathy, leading H.C. Wainwright to raise its price target to $58 and reiterate a Buy rating. The drug demonstrated significant improvement in retinopathy severity and reduced the risk of sight-threatening complications. Consequently, the probability of success for Zenkuda in diabetic retinopathy and for Zenkuda/KSI-501 in wet age-related macular degeneration has been significantly increased.
Executive pay and 2026 director vote at Kodiak Sciences (NASDAQ: KOD)
Kodiak Sciences is soliciting proxies for its 2026 Annual Meeting, where stockholders will vote on electing three Class II directors, an advisory "say-on-pay" resolution for executive compensation, and ratifying PricewaterhouseCoopers LLP as auditor. The proxy statement details that executive pay is heavily performance-based, with significant portions of CEO and CFO compensation at risk and tied to clinical, regulatory, pipeline, and financing goals. The company plans to file a Biologics License Application in diabetic retinopathy, retinal vein occlusion, and wet AMD in 2026, and highlights its Phase 3 programs and an AI-enabled retinal imaging headset.
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of "Moderate Buy" from Brokerages
Kodiak Sciences Inc. (NASDAQ:KOD) has received a "Moderate Buy" average recommendation from eight brokerages, with five buy ratings, two hold ratings, and one sell rating. The average 12-month price target is $35.43, though some analysts have recently raised their targets significantly. Despite being unprofitable, the clinical-stage biopharmaceutical company, which focuses on retinal diseases, is trading near its 12-month high, and institutional investors hold a significant portion of its stock.
Kodiak Sciences Inc stock hits 52-week high at $46.69
Kodiak Sciences Inc. stock recently achieved a 52-week high of $46.69, reflecting a remarkable 1-year return of nearly 1,481% and strong investor confidence. Despite an InvestingPro analysis suggesting the stock is overvalued, the company reported positive Phase 3 study results for Zenkuda in diabetic retinopathy and promising Phase 1b data for KSI-101 in macular edema. These clinical advancements have led to an increased price target from H.C. Wainwright.
Kodiak Sciences (KOD) reports Q4 EPS of ($1.05)
Kodiak Sciences (KOD) reported a Q4 EPS of ($1.05). This financial update provides key performance indicators for the company's recent quarter.
Kodiak Sciences KOD Stock Soars On Phase 3 Win
Kodiak Sciences (KOD) stock surged over 12% following positive Phase 3 clinical trial results for its drug Zenkuda in diabetic retinopathy. The company's GLOW2 data showed robust efficacy and safety, leading to analyst upgrades and positioning Kodiak for an accelerated multi-indication BLA filing. Despite ongoing quarterly losses, the successful trial has significantly re-rated the stock as traders eye future catalysts.
Kodiak Sciences (NASDAQ: KOD) CFO exercises options, now holds 211,930 shares
Kodiak Sciences' Chief Financial Officer, John A. Borgeson, exercised stock options for 28,614 shares of common stock at $1.04 per share. This transaction, revealed in a Form 4 filing, resulted in him directly owning 211,930 common shares, with an additional 30,000 options remaining. The options were fully vested, indicating a routine compensation event.
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Up 39.8% in March
Kodiak Sciences Inc. (NASDAQ:KOD) experienced a significant 39.8% increase in short interest during March, reaching 9,854,423 shares, which represents about 29.5% of its stock. The company's shares dropped 6.9% to $41.98 after reporting a quarterly loss of ($1.04) per share, missing estimates. Despite the mixed analyst ratings, with UBS raising its target to $80 and MarketBeat showing a "Moderate Buy" consensus with a $35.43 average target, institutional investors hold a substantial 89.06% of the stock.
Kodiak Sciences Stock Price Drops 5.5%
Kodiak Sciences Inc. (NASDAQ:KOD) saw its stock price drop 5.5% during mid-day trading due to the inherent volatility of clinical-stage biotech companies. Investors are closely watching the company as it develops its lead drug candidate, KSI-301, for retinal diseases. The decline reflects the high-risk, high-reward nature of biotech investments and the uncertainties surrounding drug development and regulatory approvals.
Is Kodiak Sciences (KOD) Balancing Dilution Risk And Survival After Auditor's Going Concern Opinion?
Kodiak Sciences (KOD) reported widening net losses for Q4 and FY 2025 and filed a significant shelf registration for shares. Concurrently, their auditor, PricewaterhouseCoopers LLP, issued a going concern warning, raising doubts about the company's ability to continue operations. This places increased scrutiny on Kodiak Sciences' funding, potential dilution, and balance sheet resilience, despite recent clinical successes.
Kodiak Sciences Stock Soars to New 52-Week High
Kodiak Sciences (NASDAQ:KOD) stock recently hit a new 52-week high, closing at $44.63 after trading as high as $46.67. This surge indicates growing investor confidence in the biopharmaceutical company's pipeline of experimental eye treatments, particularly its lead candidate KSI-301. Analysts from UBS Group and HC Wainwright have raised their price targets significantly, underscoring the positive outlook for Kodiak Sciences' clinical development efforts.
Kodiak Sciences stock hits 52-week high at $45.73 By Investing.com
Kodiak Sciences (KOD) stock surged to a 52-week high of $45.73, marking a 1961.47% increase over the past year and raising its market capitalization to $2.76 billion. Despite this impressive performance, InvestingPro analysis suggests the stock may be overvalued. The rally follows positive results from the GLOW2 Phase 3 study for its diabetic retinopathy treatment Zenkuda and promising Phase 1B APEX trial results for KSI-101, leading H.C. Wainwright to raise its price target.
Kodiak Sciences stock hits 52-week high at $45.73
Kodiak Sciences (KOD) stock reached a new 52-week high of $45.73, marking a 1961.47% increase over the past year and pushing its market cap to $2.76 billion. This surge is fueled by positive results from its GLOW2 Phase 3 study for diabetic retinopathy treatment and favorable analyst ratings from H.C. Wainwright, which raised its price target for Kodiak Sciences from $38 to $58. Despite the impressive growth, InvestingPro analysis suggests the stock may be overvalued.
Kodiak Sciences (KOD) reports Q4 EPS of ($1.05)
Kodiak Sciences (KOD) reported a Q4 EPS of ($1.05). This financial update provides key information on the company's performance during the fourth quarter. Further details would typically include revenue figures and other financial metrics to give a complete picture of their financial health.
Is Kodiak Sciences (KOD) Balancing Dilution Risk And Survival After Auditor's Going Concern Opinion?
Kodiak Sciences (KOD) reported wider net losses for Q4 and full-year 2025 and filed an $83.15 million shelf registration for shares. Auditor PricewaterhouseCoopers LLP issued an unqualified opinion but raised concerns about the company's ability to continue as a going concern, highlighting funding and dilution risks. Despite a recent Phase 3 success, investors are focused on the balance sheet resilience given the significant cash burn and auditor's warning.
Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)
Kodiak Sciences Inc. (NASDAQ:KOD) reported a Q4 EPS of ($1.05), an increase from (84c) last year, with CEO Victor Perlroth highlighting positive Phase 3 GLOW2 study results and progress in late-stage programs. UBS and H.C. Jefferies both raised their price targets on KOD shares, maintaining a Buy rating, citing improved safety and efficacy in GLOW2 results and the potential for tarcocimab VEGF and IL6. The company is focused on developing therapies for retinal diseases.
Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)
Kodiak Sciences Inc. (NASDAQ:KOD) reported a Q4 EPS of ($1.05), which was higher than the (84c) from the previous year. The company's CEO, Victor Perlroth, M.D., highlighted positive Phase 3 topline results from the GLOW2 study and advancements in their late-stage and pipeline programs. Analysts from UBS and H.C. Jefferies have raised their price targets for KOD, citing improved safety and efficacy data and a positive outlook on the company's therapies for retinal diseases.
KOD SEC Filings - Kodiak Sciences Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Kodiak Sciences Inc. (KOD) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading activities. It highlights how investors can access these documents through Stock Titan to gain insights into the company's financial health, operational progress, and material events. The platform also offers AI-powered tools to summarize complex filings and analyze key disclosures.
Kodiak Sciences shares jump on encouraging Phase 3 trial results
Kodiak Sciences shares surged following positive Phase 3 trial results for its drug tarcocimab. The study met its primary endpoint of non-inferiority to aflibercept in treating diabetic macular edema, with no new safety signals observed. These results position tarcocimab as a potential best-in-class treatment.
Kodiak Sciences Achieves Strong Gains with Positive GLOW2 Trial Results
Kodiak Sciences (NASDAQ: KOD) has seen its stock rise by 9.28% following positive results from its GLOW2 Phase 3 trial for the drug Zenkuda, along with strategic financial moves. The company reported an increase in Q4 losses but has bolstered its cash reserves to over $200 million and secured favorable analyst upgrades. Despite increased R&D expenses and negative profitability ratios, market confidence in Kodiak's pipeline and long-term potential remains strong.
Kodiak Sciences (KOD) Is Up 9.8% After Wider Loss, Going Concern Note And BLA Acceleration
Kodiak Sciences (KOD) reported a wider full-year net loss and its auditor raised going concern doubts, despite positive Phase 3 data for its Zenkuda biologic and plans to accelerate a multi-indication Biologics License Application. This creates a dichotomy between the company's advancing clinical pipeline and its pressured financial profile. While the scientific narrative has improved, financing and potential dilution risks remain prominent.
